Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, will host a conference call for the investment community
to pose questions related to the Company’s third quarter 2020
financial and operating results. The call will be held because of
technical issues experienced by the Company’s external conference
call host during the earnings call that took place on November 9 at
4:30 pm. The call will be held following the close of U.S.
financial markets on Tuesday, November 10, 2020.
Conference call details are as follows:
||November 10, 2020
||4:30 p.m. U.S. Eastern Time (ET)
||(877) 212-6076 (Domestic) or (707) 287-9331
||www.novavax.com, “For Investors”/ “Events”
|Conference call webcast replay:
||Starting at 7:30 p.m. ET, November 10, 2020 until 7:30 p.m. ET
November 17, 2020
||(855) 859-2056 (Domestic) or (404) 537-3406
||www.novavax.com, “For Investors”/ “Events” until
Novavax, Inc. (Nasdaq: NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases.
Novavax is currently conducting multiple clinical trials for
NVX-CoV2373, its vaccine candidate against the virus that causes
COVID-19, including a pivotal Phase 3 clinical trial in the United
Kingdom to evaluate the efficacy, safety and immunogenicity in
individuals aged 18-84 years of age. NanoFlu™, its
quadrivalent influenza nanoparticle vaccine, met all primary
objectives in its pivotal Phase 3 clinical trial in older adults.
Both candidate vaccines incorporate Novavax’ proprietary
saponin-based Matrix-M™ adjuvant to enhance the immune response and
stimulate high levels of neutralizing antibodies. Novavax is a
leading innovator of recombinant vaccines; its proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Historical Stock Chart
From Dec 2020 to Jan 2021
Historical Stock Chart
From Jan 2020 to Jan 2021